Enimmune Corporation (TPEX: 6564)
Health Care · Biotechnology · TW
NT$16.35
-0.61% today · -21.8% 1Y
Enimmune Corporation (TPEX: 6564) operates in the Biotechnology industry within the Health Care sector. The company is valued at $36.35M and employs 27 people.
Over the last twelve months the share price has lost 21.8%, trading between 14.90 and 23.90.
Tweenvest scores Enimmune Corporation across four factors: quality 34/100, value 67/100, growth 99/100. Its strongest factor is growth.
6564 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $36.35M
- Revenue (TTM)
- $1.68M
- P/E
- —
- EPS
- -1.68
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- NT$23.90
- 52-week low
- NT$14.90
- Avg volume (3M)
- —
- Shares outstanding
- 72.13M
- Employees
- 27
- Next earnings
- —
About Enimmune Corporation
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
- ISIN
- TW0006564008
- Founded
- 2014
- Listed since
- Sep 18, 2018
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sprint Bioscience AB (publ)OM: SPRINT | $37.82M | Skr3.55 | -2.74% |
| Novacyt S.A.ENXTPA: ALNOV | $37.63M | €0.46 | +1.20% |
| Cantargia AB (publ)OM: CANTA | $37.18M | Skr1.31 | -4.67% |
| NeoCore Technology Co., Ltd.TPEX: 4131 | $37.10M | NT$30.20 | -3.21% |
| Mendus AB (publ)OM: IMMU | $36.16M | Skr5.40 | -6.09% |
| Actinium Pharmaceuticals, Inc.NYSEAM: ATNM | $35.53M | $1.13 | +2.73% |
| Transcenta Holding LimitedSEHK: 6628 | $35.36M | HK$0.65 | -19.75% |
| NanoViricides, Inc.NYSEAM: NNVC | $35.22M | $1.38 | +6.15% |
Figures last refreshed Oct 18, 2026.